Locate your nearest distributor

Text search:
Forgot password?
Annual Report 2016
Biohit Group Financial Statement Release 2016
GastroPanel interpretation
Acetium partnering
Study Protocols

Groundbreaking Diagnostics

Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit’s mission is “Innovating for Health”.

Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit’s Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki since 1999, Small cap/Healthcare.

Study Protocols

Biohit shares study protocols, i.e., descriptions of clinical studies designed for validation of Biohit Oyj’s diagnostic tests as well as for evaluation of therapeutic efficacy of Biohit’s Acetium capsule and lozenge products in current and novel clinical indications.


Biohit's products and services are safe, ethical and costefficient innovations for diagnosing and preventing gastrointestinal diseases and the associated risks.

Annual General Meeting 2017

Biohit Oyj shareholders are invited to attend the company’s Annual General Meeting to be held on Wednesday, April 26, 2017 starting at 5:00 pm at Pörssitalo. The address is Fabianinkatu 14, 00100 Helsinki. The reception of shareholders registered for the meeting and the distribution of voting slips will commence at 4:00 pm.

Registration to annual general meeting